Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/21/2026

1. SPY
2. TSLA
3. WBD
4. NVDA
5. AMD
6. USO
7. AMC
8. META
9. MSFT
10. AMZN

Go back to Theravance Biopharma, Inc. Announces Top-line Results from Phase 2b Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis
(NASDAQ: TBPH) Delayed: 17.06 +0.04 (0.24%)
Previous Close $17.02    52 Week High $38.92 
Open $17.03    52 Week Low $12.87 
Day High $17.07    P/E N/A 
Day Low $17.03    EPS $0.00 
Volume 286,863